Menthol citrate ester modulates epithelial alarmin–type 2 immune responses in OVA-induced allergic airway inflammation
Authors:
- Jing ZhangJZJing Zhang
- Juehui ZengJZJuehui Zeng
- Baoyi LinBLBaoyi Lin
- Chang LiuCLChang Liu
- Xinyu ZhangXZXinyu Zhang
- Guogang XuGXGuogang Xu
- Jiawei WanJWJiawei Wan
- Zheng WangZWZheng Wang
- Yingzhen DuYDYingzhen Du
Open Access
- 27 October 2026
- journal article
- Published by Tsinghua University Press in Nano Research
- Vol. 20 (1)
Abstract
Menthol citrate ester (MC) is a chemically defined menthol-derived compound, but its inhalation safety and timing dependent effects on allergic airway inflammation remain unclear. Here, the inhalation safety and biological effects of aerosolized MC were evaluated through in vitro and in vivo approaches. Acute inhalation exposure resulted in no mortality, exposure-related clinical signs, hematological or biochemical alterations, or evident histopathological injury in mice, while MC maintained cytocompatibility in RAW264.7 cells at concentrations up to 500 μg/mL. In an ovalbumin (OVA)-induced allergic airway inflammation model, post-challenge MC treatment reduced serum total and OVA-specific immunoglobulin E (IgE), suppressed IL-13, IL-5, IL-33, thymic stromal lymphopoietin (TSLP), C-C motif chemokine ligand 11 (CCL11), interleukin-6 (IL-6), and IL-1β levels in bronchoalveolar lavage fluid (BALF), and decreased eosinophil and neutrophil accumulation. Histological analyses showed reduced airway inflammation, mucus hypersecretion, and collagen deposition. In contrast, pre-challenge administration failed to provide protection and further increased several inflammatory indices. Bulk RNA sequencing showed that high-dose therapeutic MC partially reversed OVA-induced transcriptional programs associated with epithelial alarmin signaling, type 2 inflammation, eosinophil recruitment, mucus production, airway remodeling, inflammatory amplification, and sensory-response regulation. Quantitative polymerase chain reaction (qPCR) confirmed downregulation of Il33, Il1rl1, Mmp9, and Htr3a, while Western blotting showed reduced IL-33, suppression of tumorigenicity 2 (ST2)/interleukin 1 receptor-like 1 (IL1RL1), matrix metallopeptidase 9 (MMP9), and 5-hydroxytryptamine receptor 3A (HTR3A) protein expression. These findings support the preliminary inhalation safety of MC and demonstrate a timing-dependent therapeutic effect in established allergic airway inflammation.Keywords
This publication has 61 references indexed in Scilit:
- From barrier dysfunction to systems immunology: Emerging paradigms in personalized immune-mediated diseaseAllergy Medicine, 2026
- A Biologically Lubricating Allicin‐Based Nanoplatform for Remodeling the Inflammation‐Senescence Axis in the Treatment of PeriodontitisAdvanced Materials, 2026
- Mcl-1-dependent stabilization of GATA3 and apoptosis resistance: A KDM4D-regulated pathway in airway allergyAllergy Medicine, 2026
- Exploring the kidney-tonifying effect of Qi-Xian decoction for asthma treatment by modulating the proliferation and migration of endogenous BMSCsChinese Journal of Natural Medicines, 2025
- A new phenolic acid isolated from Salvia miltiorrhiza ameliorates OVA-induced allergic asthma by regulation of Th17/Treg cells and inflammation through the TLR4 pathwayChinese Journal of Natural Medicines, 2025
- Inflammatory memory in allergic diseasesAllergy Medicine, 2025
- New delivery systems potential for current anti-allergy drugsAllergy Medicine, 2024
- Cytokines reprogram airway sensory neurons in asthmaCell Reports, 2024
- Biomimetic injectable hydrogel microspheres with enhanced lubrication and controllable drug release for the treatment of osteoarthritisBioactive Materials, 2021
- Eosinophils and the Ovalbumin Mouse Model of Asthma2014